Real-World Outcomes of Immunotherapy in Second- or Later-Line Non-Small Cell Lung Cancer with Actionable Genetic Alterations

Real-World Outcomes of Immunotherapy in Second- or Later-Line Non-Small Cell Lung Cancer with Actionable Genetic Alterations

Introduction: While the efficacy of immune checkpoint inhibitors (ICIs) in treating non-small cell lung cancer (NSCLC) patients with actionable genetic alterations (AGAs) is modest, certain patients demonstrate improved survival. Thus, this study aimed to evaluate the benefits of ICIs in NSCLC patie...

Full description

Bibliographic Details
Main Authors: Soojin Jun, Sehhoon Park, Jong-Mu Sun, Se-Hoon Lee, Jin Seok Ahn, Myung-Ju Ahn, Juhee Cho, Hyun Ae Jung
Format: Article
Language:English
Published: MDPI AG 2023-11-01
Series:Cancers
Subjects:
non-small cell lung cancer
immune checkpoint inhibitors
actionable genetic alterations
predictive biomarkers
Online Access:https://www.mdpi.com/2072-6694/15/22/5450

Similar Items

Similar Items